haemate p 500iu fviii/1200iu vwf powder and solvent for solution for injection/ infusion
csl behring gmbh - human blood coagulation factor viii, human von willebrand factor (vwf:rco) - powder and solvent for solution for injection/ infusion - 500iu+ 1200iu
octanate, 100 iu/ml powder and solvent for solution for injection
octapharma (ip) limited - factor viii, human - powder and solvent for solution for injection - factor viii, human 100 iu/ml - antihemorrhagics
alphanate (antihemophilic factor/von willebrand factor complex- human kit
grifols usa, llc - human coagulation factor viii/von willebrand factor complex (unii: 5t6b772r4q) (human coagulation factor viii/von willebrand factor complex - unii:5t6b772r4q) - human coagulation factor viii/von willebrand factor complex 250 [iu] in 5 ml - alphanate, (antihemophilic factor/von willebrand factor complex [human]), is indicated for: - control and prevention of bleeding episodes and perioperative management in adult and pediatric patients with factor viii (fviii) deficiency due to hemophilia a. - surgical and/or invasive procedures in adult and pediatric patients with von willebrand disease (vwd) in whom desmopressin (ddavp) is either ineffective or contraindicated. it is not indicated for patients with severe vwd (type 3) undergoing major surgery. alphanate is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components [see adverse reactions (6) ]. pregnancy category c. animal reproduction studies have not been conducted with alphanate. it is also not known whether alphanate can cause fetal harm when administered to a pregnant woman or affect reproductive capacity. alphanate should be given to a pregnant woman only if clearly needed. no human o
wilate pdr+solv for soln for inj 100iu/ml (1000iu)
octapharma (ip) limited - human von willebrand factor; human coagulation factor xiii - powder and solvent for solution for injection - human von willebrand factor 1000 iu; human coagulation factor xiii 1000 iu - antihemorrhagics
wilate pdr+solv for soln for inj 100iu/ml (500iu)
octapharma (ip) limited - human von willebrand factor; human coagulation factor viii - powder and solvent for solution for injection - human von willebrand factor 500 iu; human coagulation factor viii 500 iu - antihemorrhagics
recombinate antihaemophilic factor 250 iu international unit pdr+solv for soln for inj
baxter healthcare limited - factor viii, human recombinant - pdr+solv for soln for inj - 250 iu international unit
recombinate 1000 iu, powder and solvent for solution for injection
baxalta innovations gmbh - factor viii, human recombinant - powder and solvent for solution for injection - 1000 iu international unit(s) - blood coagulation factors; coagulation factor viii - antihaemorrhagics: blood coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). this product does not contain von willebrand factor and is therefore not indicated in von willebrand’s disease
recombinate 500 iu, powder and solvent for solution for injection
baxalta innovations gmbh - factor viii, human recombinant - powder and solvent for solution for injection - 500 iu international unit(s) - blood coagulation factors; coagulation factor viii - antihaemorrhagics: blood coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). this product does not contain von willebrand factor and is therefore not indicated in von willebrand’s disease.
csl hong kong aleviate human coagulation factor viii 500iu/von willebrand factor 1000iu complex, powder for injection (50 iu/ml fviii)
csl behring australia pty ltd - von willebrand factor, quantity: 1000 iu; factor viii, quantity: 500 iu - injection, solution - excipient ingredients: water for injections - aleviate is indicated for: ? the treatment of bleeding episodes including surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. ? the treatment and prophylaxis of bleeding associated with factor fviii deficiency due to haemophilia a.
immunate 1000iu+750iu powder and solvent for solution for injection
baxter ag - human blood coagulation factor viii, von willebrand factor(vwf:rco) - powder and solvent for solution for injection - 1000iu+750iu